Dana-Farber Cancer Institute clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
18 trials changed in the last 30 days: 0 stopped, 9 with notable changes, 9 with minor changes only.
- Minor: Nivolumab or Nivolumab/Ipilimumab · Progessive/ Recurrent Meningioma Study completion pushed from Oct 1, 2026 to Apr 1, 2027
- Minor: Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Study completion pushed from Dec 2026 to Dec 2027
- Minor: ACT · Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) Primary completion date changed from estimate of Sep 24, 2026 to Oct 26, 2026
- Minor: RISE in HR NBL · Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma Trial sites expanded: 6 → 9 locations
- Notable: ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL Primary completion moved earlier from Apr 2026 to Jun 2019
- Notable: COMPASSION Study Primary completion pushed from Oct 1, 2026 to Oct 1, 2028
- Notable: HYPE · High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study Primary completion pushed from Sep 24, 2026 to Sep 24, 2027
- Minor: RECTIFY-1 · Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer Primary completion pushed from Jan 1, 2027 to Jun 1, 2027
- Minor: Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Trial completed
- Notable: Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue Primary completion pushed from Aug 31, 2026 to Aug 31, 2027
- Notable: Resistance and Aerobic Exercise for Prevention · Dense Breasts (REP-D) Primary completion pushed from Sep 30, 2026 to Sep 30, 2027
- Notable: Dance Study for Post-surgical Pain in Breast Cancer Survivors Primary completion pushed from Feb 28, 2026 to Sep 28, 2027
- Notable: SMARCA4/2 Inhibitor for POU2F3-Positive SCLC Recruitment opened
- Minor: RESTART · Impact of Exercise on the Complications of Corticosteroids · GVHD: the RESTART Trial Enrollment closed, study ongoing
- Minor: IPI-145 Plus FCR in Previously Untreated, Younger · CLL Study completion pushed from Jul 2026 to Dec 2026
- Minor: Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML Study completion pushed from Sep 1, 2026 to Dec 1, 2026
- Notable: I-MAC · Ivonescimab · Advanced, Metastatic Salivary Gland Cancers Primary completion pushed from Jul 1, 2026 to Jul 1, 2027
- Notable: Nivolumab and Ipilimumab in Children and Young · INI1-Negative Cancers Results posted: Oct 20, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-16 | NCT07938463 Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC | Phase 1 | Not Yet Recruiting |
| 2026-11-06 | NCT07921589 Pilot Testing ACCOMPANI: A Nurse-Targeted Intervention to Promote Psychosocial Equity in… | Not Yet Recruiting | |
| 2026-10-27 | NCT07898813 Daraxonrasib in Resectable PDAC | Phase 1 | Not Yet Recruiting |
Active trials by phase
| Early Phase 1 | 5 | |
| Phase 1 | 35 | |
| Phase 1/2 | 12 | |
| Phase 2 | 70 | |
| Phase 3 | 2 | |
| Phase 4 | 1 |
Not charted: 109 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 41
Breast Cancer (46) · Leukemia (35) · Lung Cancer (18) · Head & Neck Cancer (14) · Acute Myeloid Leukemia (AML) (11) · Chronic Lymphocytic Leukemia (CLL) (11) · Endometrial Cancer (11) · Multiple Myeloma (11) · Prostate Cancer (11) · Myelodysplastic Syndromes (MDS) (9)
Get alerts when Dana-Farber Cancer Institute's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.